FDA Brief

Warning letters Drugs

FDA warning letter to

MaxLife Technologies Inc. dba Maxlife

MediumIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.

What happened

FDA reviewed the website maxlife.com in December 2025 and found it offering compounded semaglutide and tirzepatide drug products. The pictured labels showed the name "Maxlife," suggesting Maxlife is the compounder when it is not, and the site called the products "FDA Approved" and "clinically tested and FDA-approved" with the same active ingredients as Wegovy, Ozempic, Mounjaro and Zepbound. FDA said compounded drugs are not FDA-approved and that these claims make the products misbranded.

What FDA found

  1. The website showed product labels bearing the name Maxlife, which suggests Maxlife made the drugs when it did not.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR 201.1(h)(2)
  2. The site called the compounded drugs "FDA Approved" and "clinically tested and FDA-approved," but compounded drugs are not FDA-approved.

    FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The site used phrases such as "generic compounded medication" and "active ingredients in Ozempic & Wegovy," which mislead buyers about what the products are.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  4. Shipping these misbranded drugs across state lines is a prohibited act.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  5. Compounded drugs must meet the conditions of section 503A or 503B to be exempt from the new drug approval requirements.

    FDCA sections 503A and 503B [21 U.S.C. §§ 353a, 353b]

What FDA wants

Within 15 working days, respond to the Office of Compounding Quality and Compliance describing the specific steps taken to fix the violations and prevent recurrence, including identifying who makes the compounded products, providing sample labeling, and correcting or removing the misleading claims.

Who should pay attention

  • telehealth companies selling compounded semaglutide or tirzepatide
  • compounding pharmacies whose products are resold by online marketers
  • marketing and compliance teams running online pharmacy websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low